

Applicants submit that neither prong of this test is met by the present Restriction Requirement. First, the inventions are not independent or distinct as claimed. The method of inhibiting IL-1 β inflammatory activity uses the compounds of the present invention. Hence, it cannot cause a serious burden on the Examiner if restriction is not required.

Moreover, the Examiner requires election of one of the species of diseases set forth in the dependent "method" claims. Applicants herein elect with traverse "dermal inflammatory disorder". Applicants do not acquiesce that the species are patentably distinct. Rather, each of these diseases is caused at least in part by inflammatory activity. Hence, administering the compounds of the present invention necessarily ameliorates symptoms and interferes with the pathology demonstrated.

CONCLUSION

It is believed that the claims are now in condition for allowance and rapid advancement as such is earnestly solicited. If any issues or questions arise that may be resolved by way of a telephonic interview, the Examiner is invited to contact the undersigned at the telephone number provided below.

Respectfully submitted,

Date: December 20, 1999


Albert P. Halluin (Reg. No. 25,227)

HOWREY & SIMON
Box No. 34
1299 Pennsylvania Avenue, N.W.
Washington, D.C. 20004-2402
(650) 463-8100